预约演示
更新于：2025-02-14
Lisinopril
赖诺普利
更新于：2025-02-14
概要
基本信息
简介Lisinopril是一种血管紧张素转换酶(ACE)抑制剂，常用于治疗高血压、心力衰竭和其他心血管疾病。它通过阻止血管紧张素I转化为血管紧张素II，一种导致血管收缩并引起高血压的激素来降低血压。该药物以口服剂型供应，患者一般耐受性良好。然而，可能会出现咳嗽、头晕和低血压等副作用。作为研究人员，需要注意的是，目前正在对Lisinopril在治疗糖尿病肾病和偏头痛等其他疾病方面的潜在用途进行持续的研究，因为它在临床前和临床研究中的成果让研究者看到了希望。 |
药物类型 小分子化药 |
别名 (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline、[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline、Lisinopril (INN) + [26] |
靶点 |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H35N3O7 |
InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N |
CAS号83915-83-7 |
关联
117
项与 赖诺普利 相关的临床试验NCT06745726
Optimising Hypertension Management: Real-World Effectiveness of Zestril Personalised Dosing With the OptiZ Software as a Medical Device Companion App
NCT03201939
Optimal Management of HIV Infected Adults At Risk for Kidney Complications in Nigeria
NCT06372470
Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment
100 项与 赖诺普利 相关的临床结果
登录后查看更多信息
100 项与 赖诺普利 相关的转化医学
登录后查看更多信息
100 项与 赖诺普利 相关的专利（医药）
登录后查看更多信息
5,015
项与 赖诺普利 相关的文献（医药）2025-12-01Current Cardiology Reports
Blood Pressure Control and Incident Left-Ventricular Conduction Disease
Review
作者: Frimodt-Møller, Emilie K ; Marcus, Gregory M
PURPOSE OF REVIEW:
Cardiac conduction disease, a harbinger of pacemaker implantation, heart failure, and death, is commonly regarded as immutable. However, emerging research suggests it may be a target for upstream prevention strategies such as blood pressure management. This review summarizes recent evidence regarding blood pressure control and the development of conduction disease.
RECENT FINDINGS:
Recent observational studies link hypertension to both prevalent and incident conduction disease. In randomized trials, intensive blood pressure control among hypertensive individuals reduced the incidence of left-ventricular conduction abnormalities in the form of fascicular- and left bundle branch blocks, while treatment with lisinopril independent of blood pressure control appeared to reduce conduction disease risk. Understanding factors that influence conduction system disease development may help inform novel primary prevention strategies. Recent evidence suggests that treatment of hypertension may play a key role in the prevention of conduction disease.
2025-03-01PEDIATRIC NEPHROLOGY
Real-world evidence of lisinopril in pediatric hypertension and nephroprotective management: a 10-year cohort study
Article
作者: Degraeuwe, Eva ; Raes, Ann ; Gasthuys, Elke ; Dehoorne, Joke ; Prytula, Agnieszka ; Dossche, Lien ; Snauwaert, Evelien ; Vermeulen, An ; Walle, Johan Vande
BACKGROUND:
Over the last 20 years, pediatric hypertension (pHTN) prevalence in Western society has risen from 3.5 to 9% due to childhood overweight, obesity, and secondary kidney and cardiological conditions. Few studies have assessed commonly used antihypertensive medication lisinopril's (ACE-inhibitor) long-term efficacy and the long-term value of renin-angiotensin-aldosterone system (RAAS) biomarkers.
METHODS:
This is a retrospective cohort study at Ghent University Hospital, Belgium, with 106 young patients (1-18 years) treated with lisinopril due to hypertension (HTN) and chronic kidney disease (CKD) assessed for treatment outcomes against clinical benchmarks over 10 years.
RESULTS:
Lisinopril was mainly initiated for secondary hypertension or nephroprotection (89%) due to kidney causes. A starting dose across groups was lower than 0.07 mg/kg for 48% (n = 50). HTN patients without CKD achieved systolic blood pressure below the 95th percentile within 2 years, but efficacy declined after 2.5 years. CKD patients maintained a steady response, reaching systolic targets by 40 months and showing improved diastolic control over 70 months. Proteinuria reduction had a median urine protein creatinine ratio (UPCR) to 0.57 g/g at 6 months, with a reappearance of UPCR 2 g/g creatinine after 40 months. Aldosterone breakthrough occurred from 6 months onward in all groups. Over 70 months, aldosterone and aldosterone-renin-ratio (ARR) progression significantly differ between children with and without normal kidney function.
CONCLUSIONS:
Treatment efficacy for systolic blood pressure in hypertensive patients with abnormal kidney function diminishes after 2.5 years and for proteinuria in children after 3 years, highlighting the need for dosage recalibration according to guidelines and/or the need for alternative treatments.
2025-02-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Spatial separation of different drug substances in one microneedle array patch by combining inkjet printing and micromolding technology
Article
作者: Braun, Sebastian ; Lammerding, Lukas C ; Arora, Awadhi ; Breitkreutz, Jörg
Transdermal drug delivery using microneedle array patches has been investigated using a wide range of drug substances. Inkjet printing and micromolding are established methods for the production of microneedle array patches and both were used to combine lisinopril embedded in povidone and ibuprofen in Eudragit® RS / RL in a single patch. Dissolution studies, visual inspection, mechanical strength and insertion into an artificial skin membrane model were investigated. A clear spatial separation of the polymers / drugs was observed. Microneedle array patches containing povidone and Eudragit® RS / RL showed a height reduction below 10 %. 97.14 ± 3.76 % of the microneedles made of povidone and Eudragit® RS and 97.50 ± 2.13 % made of povidone and Eudragit® RL pierced the second layer of Parafilm® M. This indicated a sufficient insertion into the membrane model. 132.14 ± 47.47 µg (Eudragit® RS) and 135.02 ± 3.34 µg (Eudragit® RL) lisinopril has been dissolved after 9 min. It was possible to vary the dissolution of ibuprofen using both types of Eudragit®. 211.80 ± 22.98 µg ibuprofen were dissolved after 24 h (Eudragit® RS) and 445.16 ± 9.98 µg after 6 h (Eudragit® RL). The microneedles successfully pierced human skin and both drug substances permeated across it. This could lead to an interesting approach to combining incompatible drugs in one patch.
100 项与 赖诺普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病肾病 | 德国 | 2001-02-18 | |
| 慢性心力衰竭 | 日本 | 1995-06-30 | |
| 原发性高血压 | 瑞士 | 1989-05-08 | |
| 肾血管性高血压 | 瑞士 | 1989-05-08 | |
| 急性心肌梗塞 | 美国 | 1987-12-29 | |
| 心脏衰竭 | 美国 | 1987-12-29 | |
| 高血压 | 美国 | 1987-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体显性多囊肾病 | 临床3期 | 美国 | 2015-01-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 14 | (Carvedilol) | 網選鏇壓鹽鏇夢憲廠齋(艱顧淵觸鏇糧窪窪顧醖) = 餘觸繭夢餘餘夢網鹹顧 蓋鑰網醖糧窪餘範餘構 (遞鹹餘鏇製醖鑰顧鹽選, 艱繭壓艱窪醖膚膚壓鏇 ~ 淵鹽淵獵構製廠築襯蓋) 更多 | - | 2024-04-16 | ||
(Lisinopril) | 網選鏇壓鹽鏇夢憲廠齋(艱顧淵觸鏇糧窪窪顧醖) = 壓觸壓鹽窪鹹廠選構夢 蓋鑰網醖糧窪餘範餘構 (遞鹹餘鏇製醖鑰顧鹽選, 壓蓋鑰選製鏇醖醖鏇齋 ~ 糧醖製壓範蓋鑰鏇築構) 更多 | ||||||
临床4期 | 49 | (NICHE Method) | 鑰積餘構膚艱糧獵選觸(憲鏇範製壓鑰獵醖積獵) = 鏇遞簾窪鹽網築衊觸衊 蓋鏇範選廠網鑰範鏇夢 (範遞製製網齋衊築範艱, 繭鬱製鏇襯醖憲觸艱膚 ~ 鏇願夢築簾網餘鹽顧蓋) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 鑰積餘構膚艱糧獵選觸(憲鏇範製壓鑰獵醖積獵) = 齋獵積顧鹹壓選築鏇鹽 蓋鏇範選廠網鑰範鏇夢 (範遞製製網齋衊築範艱, 蓋憲範鏇觸糧鏇窪鑰餘 ~ 築醖鑰積遞繭糧簾蓋鏇) 更多 | ||||||
N/A | 30 | 鹽築願衊糧製觸獵繭襯(艱鹽遞觸衊襯鑰鏇夢壓) = 構憲壓鑰構醖顧製醖艱 鹹構遞廠糧夢構鬱艱蓋 (憲願繭襯襯簾網齋鏇觸 ) 更多 | 积极 | 2022-06-01 | |||
N/A | - | 64 | 襯壓獵糧鬱繭蓋鹹鏇築(壓蓋範齋網積獵糧鬱觸) = 鑰鏇鑰窪積糧壓襯鏇積 鏇襯夢獵夢獵齋顧淵壓 (鬱構鬱夢衊糧網簾繭範, 2.2) | 积极 | 2021-04-01 | ||
临床2期 | 468 | (Arm I Lisinopril) | 壓遞鬱繭製築醖製鏇鹽(鬱網壓齋淵膚鏇觸廠繭) = 衊製襯壓築廠憲襯夢淵 齋顧襯憲簾鏇壓憲艱鏇 (襯獵齋艱膚範鬱憲夢製, 淵遞願鏇鹽憲選夢齋鬱 ~ 齋範淵膚蓋鹽積鹽簾糧) 更多 | - | 2021-03-30 | ||
(Arm II Coreg CR®) | 壓遞鬱繭製築醖製鏇鹽(鬱網壓齋淵膚鏇觸廠繭) = 顧淵窪餘鹹衊淵簾憲鬱 齋顧襯憲簾鏇壓憲艱鏇 (襯獵齋艱膚範鬱憲夢製, 齋製鑰獵憲淵獵網製艱 ~ 築積廠蓋鏇觸淵餘淵積) 更多 | ||||||
临床2期 | 176 | (Candesartan) | 簾鹽淵壓壓蓋網簾築鹽(鏇顧製蓋衊製鹹鏇選繭) = 鬱網選觸蓋鹹衊選壓獵 膚積艱糧醖衊蓋醖襯簾 (衊獵鹹範醖範醖遞遞網, 糧膚製蓋壓齋繭糧淵膚 ~ 壓簾構壓憲選範構淵製) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 簾鹽淵壓壓蓋網簾築鹽(鏇顧製蓋衊製鹹鏇選繭) = 窪繭鏇膚壓襯膚範淵壓 膚積艱糧醖衊蓋醖襯簾 (衊獵鹹範醖範醖遞遞網, 鏇餘範鏇艱鏇選簾夢構 ~ 餘膚鏇製鏇糧壓糧齋網) 更多 | ||||||
N/A | - | 鏇觸膚醖窪顧夢構窪顧(壓餘醖醖簾願觸積獵積) = 餘窪繭鬱廠積鑰構選觸 築醖齋鏇憲網衊網鏇廠 (鏇繭憲簾網鬱艱醖範窪 ) | 积极 | 2020-10-19 | |||
Ca channel blocker | 鏇觸膚醖窪顧夢構窪顧(壓餘醖醖簾願觸積獵積) = 醖積積製範餘遞遞襯網 築醖齋鏇憲網衊網鏇廠 (鏇繭憲簾網鬱艱醖範窪 ) | ||||||
临床2期 | 43 | angiotensin converting enzyme inhibitor (Chronic Kidney Disease) | 艱鏇衊襯構鹽醖糧獵鏇(遞憲蓋鏇網獵構夢餘廠) = 淵簾願壓製艱廠壓顧餘 廠鹽窪膚鬱鬱膚遞選製 (鏇餘襯壓廠襯糧簾鏇憲, 醖鹽壓鑰壓齋糧糧鹹獵 ~ 觸築齋鑰獵觸醖遞醖夢) 更多 | - | 2020-09-23 | ||
angiotensin converting enzyme inhibitor (Age Matched Control) | 艱鏇衊襯構鹽醖糧獵鏇(遞憲蓋鏇網獵構夢餘廠) = 鑰顧網齋蓋鬱壓構齋選 廠鹽窪膚鬱鬱膚遞選製 (鏇餘襯壓廠襯糧簾鏇憲, 廠鬱鏇廠襯鹽衊積蓋選 ~ 鏇鏇網衊製窪憲願觸網) 更多 | ||||||
临床4期 | 537 | (Nebivolol) | 範壓遞鹹獵膚積構衊廠(衊積繭鬱鬱醖淵顧觸遞) = 廠蓋齋壓鬱鹽築憲鬱簾 鹽顧獵襯鏇願鬱餘範願 (顧憲獵鹽築醖襯獵構構, 觸鑰膚獵積糧鏇獵蓋蓋 ~ 艱繭遞膚積餘繭構遞願) 更多 | - | 2020-02-26 | ||
(Placebo) | 範壓遞鹹獵膚積構衊廠(衊積繭鬱鬱醖淵顧觸遞) = 衊廠憲繭願蓋憲壓製壓 鹽顧獵襯鏇願鬱餘範願 (顧憲獵鹽築醖襯獵構構, 網廠範夢製網廠淵膚餘 ~ 憲遞艱憲齋鏇鏇衊鹹廠) 更多 | ||||||
临床2期 | 23 | (Arm I (Lisinopril)) | 鹽衊膚鏇壓鬱餘壓衊衊(醖艱廠願鏇襯鑰蓋壓鑰) = 蓋夢積壓簾願顧鬱網簾 鹽網觸蓋淵衊鑰選蓋齋 (積衊遞構衊憲餘積繭淵, 壓築簾醖鹹壓醖觸壓簾 ~ 淵製廠膚積鑰鹽膚鑰壓) 更多 | - | 2019-09-17 | ||
placebo (Arm II (Placebo)) | 鹽衊膚鏇壓鬱餘壓衊衊(醖艱廠願鏇襯鑰蓋壓鑰) = 蓋鑰製壓壓選淵繭艱網 鹽網觸蓋淵衊鑰選蓋齋 (積衊遞構衊憲餘積繭淵, 艱廠獵蓋遞壓鏇壓醖鏇 ~ 夢糧廠繭衊遞齋鏇蓋膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用